Introduction: The purpose of this study was to evaluate whether there are additional
| INTRODUC TI ON
Every year, many women with a history of spontaneous preterm birth and second trimester pregnancy loss are able to get a prophylactic (history-indicated) cerclage.
1 Anatomical, biochemical and clinical evidence from retrospective cohort studies and randomized clinical trials consistently support 12-14 weeks of gestation as the optimal time to place a prophylactic cerclage in at-risk women. [2] [3] [4] [5] [6] However, despite the effectiveness of history-indicated cerclage in reducing the risk of spontaneous preterm birth, about one-third of women that receive prophylactic cerclage still deliver preterm.
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This makes adjunctive therapies appealing options in maximizing the effectiveness of prophylactic cervical cerclage in prolonging pregnancy.
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The use of 17-alpha hydroxyprogesterone caproate has been associated with a greater than 30% decrease in recurrence of preterm birth in women with prior spontaneous preterm birth between 20 and 36 weeks. [11] [12] [13] [14] [15] At 16 weeks of gestation, some obstetricians begin 17-OHPC in women with history-indicated cerclage and continue it until 36 completed weeks of gestation. When 17-OHPC is used in combination with prophylactic cerclage, it is thought to prevent preterm birth due to the synergistic effect of both therapies. The rationale for this is that 17-OHPC is thought to act as an anti-inflammatory agent and a potent inhibitor of the formation of gap-junctions between myometrial cells, thereby preventing preterm labor onset and increasing the duration of pregnancy. 16 However, the routine use of 17-OHPC is controversial, in part because no adequately powered prospective studies or randomized clinical trials have directly evaluated the efficacy of combination therapy (prophylactic cerclage + 17-OHPC) in this patient population. In addition, health insurance companies continually refused to issue prior authorizations to commence 17-OHPC as adjunctive therapy in women with a history-indicated cerclage, asserting that it remains investigational in this setting and is not supported by available data. 17, 18 One recent retrospective cohort study reported that combination therapy (cerclage+17-OHPC) was more effective than cerclage alone for preventing spontaneous preterm birth at less than 24 weeks, but not at less than 28 or 37 weeks of gestation. 8 However, the small number of spontaneous preterm births <24 weeks in this study precludes a clear conclusion about the efficacy of combined therapy. In addition, other studies that used combination therapy did not show differences in the rates of spontaneous preterm birth comparing history-indicated cerclage+17-OHPC with cerclage alone. 9, 10, 19 Thus, use of combination therapy (both prophylactic cerclage and 17-OHPC) is neither well supported nor refuted by currently available data.
Therefore, the aim of this systematic review and meta-analysis was to synthesize comprehensively the literature on the efficacy of combination therapy (prophylactic cerclage+17-OHPC) compared with prophylactic cerclage alone in women considered to be at increased risk of spontaneous recurrent preterm birth.
| MATERIAL AND ME THODS

| Data sources
The methodology of this systematic review and meta-analysis conformed to the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines. 20 We searched ClinicalTrials.gov, MEDLINE, EMBASE, Scopus, Web of Science and the Cochrane Library for studies that met our inclusion and exclusion criteria using a search strategy designed in collaboration with an experienced Librarian at the Johns Hopkins University School of Public Health. Our PubMed search incorporated both controlled MEDLINE vocabulary (ie MeSH terms) and free text keywords.
Our search included controlled vocabulary terms (MeSH and free text keywords) for 17-hydroxyprogesterone or history-indicated There were no differences in fetal birthweight, respiratory distress syndrome or necrotizing enterocolitis comparing cerclage alone with cerclage+17-OHPC. cerclage (study intervention), preterm birth (study outcome), pregnancy (study population) and cohort/randomized controlled trial (study design). The search strategy included Boolean operators "OR" (for related term) and "AND" (combination of different concepts). Our ClinicalTrials.gov search strategy incorporated similar search strategy, without incorporating the "cohort" and "randomized controlled trial" terms. Relevant synonyms and alternative spellings were identified via the EMBASE controlled vocabulary Emtree.
Conclusions
| Main outcome measures
The primary outcome of interest of this systematic review is the proportion of preterm birth at less than 24 weeks of gestation, because 24 weeks or greater is considered a viable gestational age for neonatal intervention in most centers. We assessed for the following secondary outcomes: preterm birth at <37 weeks of gestation, preterm birth at <28 weeks, respiratory distress syndrome, necrotizing enterocolitis, fetal birthweight, neonatal intensive care unit (NICU) stay, mean gestational age at delivery, fetal and neonatal death, neurological morbidity (intraventricular hemorrhage and periventricular leukomalacia), neonatal sepsis and a composite of severe neonatal morbidity. Severe neonatal morbidity was defined as a composite measure of periventricular leukomalacia, intraventricular hemorrhage (grades III and IV), surgical necrotizing enterocolitis (requiring surgical treatment or peritoneal drainage) or respiratory distress syndrome. All primary and secondary outcomes were assessed as risk ratios, except fetal birthweight, which was compared as a difference of means.
| Eligibility criteria
The protocol for this review was registered in the PROSPERO International Prospective Register of Systematic Reviews (CRD42018094559) before data extraction following the PRISMA guidelines for protocols (PRISMA-P quality of evidence was assessed using the Grading quality of evidence and strength of recommendations (GRADE) guidelines
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( Table 2 ). The GRADE guideline covers risk of bias, inconsistency, indirectness, imprecision and publication bias. The overall quality of evidence was reported for each outcome measure as high, moderate, low or very low. 
No. of patients Effect
Quality of evidence (GRADE) Importance
History-indicated cerclage alone
History-indicated
| Data collection and analysis
We obtained missing information and other relevant data via email requests to the contact authors of the included studies and the Johns Hopkins University Welch library. For the purpose of this review, we allowed a period of 1 week for the author's response. We determined whether to perform a meta-analysis based on a qualitative assessment of whether study populations and interventions were reasonably comparable. We assumed that if studies met our inclusion criteria, the outcome of recurrent spontaneous preterm birth would be comparable across studies. We also assessed clinical, methodological and statistical evidence of heterogeneity in the studies and considered this heterogeneity in our assessment to do a meta-analysis. We then performed a pairwise meta-analysis comparing cerclage+17-OHPC vs cerclage alone. We used a random-effects model, as we expected a great deal of heterogeneity in these studies given that the studies were likely to incorporate different patient populations and use varying methodologies.
In making a decision whether to present summary relative risk estimates, we considered clinical and methodological sources of heterogeneity across studies. We investigated statistical heterogeneity by calculating the Q, the I 2 and the τ 2 statistic. For the Q statistic, which tests the hypothesis of a common effect, we used a critical value of <.1 as the cutoff for statistical significance.
For the I 2 statistic, which shows the inter-study heterogeneity as a proportion of the total heterogeneity, we considered I 2 values of 25%-50%, 51%-75%, and 76%-100% to be of low, moderate and high heterogeneity, respectively. 23 We also examined the confidence intervals of the risk estimates in the Forest plots for overlap.
We reported τ 2 , which reflects the amount of true heterogeneity.
For τ 2 , we used a critical value of <1.0 as the cutoff for statistical significance. We performed sensitivity analyses to assess the impact of excluding studies with higher risk of bias. In the case of statistically significant heterogeneity (P-value of the Cochrane Q statistic <.1), the random-effects model of Der-Simonian and
Laird was used to obtain the pooled relative risk (RR) estimate.
For studies which reported both unadjusted and adjusted risk for confounders statistically proven, we performed an aggregate data meta-analysis using the generic inverse variance method to obtain the adjusted RR for the primary outcome and for the secondary outcomes in the main analysis. 24, 25 Statistical analyses were conducted with Review Manager (REVMAN) 5.3. 
| RE SULTS
| General characteristics of the studies
The search identified 732 bibliographic references, 664 through the PubMed database, and 68 through Clinicaltrials.gov ( Figure 1 ).
After 18 duplicate papers were removed, 714 records in title and abstract form were available for further screening. We excluded 691 clearly irrelevant references through reading of the abstracts. Thus, we assessed 23 references for eligibility in the systematic review. After careful scrutiny, we further excluded 18 of these references as they did not fulfil the inclusion criteria (seven studies had no information on history-indicated cerclage) as these were studies including only 17-OHPC 27-33 ; five studies had no information on 17-OHPC (studies including only history-indicated cerclage) [34] [35] [36] [37] [38] ; one publication was a letter to the editor regarding another study 39 ;
4 studies compared rates of preterm birth in women with singleton pregnancies and a prior spontaneous preterm birth who had transvaginal ultrasound-measured cervical length <25 mm before 24 weeks of gestation and received 17-OHPC, ultrasound-indicated cerclage, both or neither, [40] [41] [42] [43] and 1 paper did not specifically describe the perinatal outcomes in women with prophylactic cerclage+17-OHPC in their analysis 44 ( Figure 1 ). Subsequently, five references describing five trials met the inclusion criteria for this systematic review. The PRISMA diagram is shown in Figure 1 . Table 3 shows the summary of the participants. The studies included a total of 546 women, with 189 women receiving 17-OHPC in addition to history-indicated cerclage, and 357 receiving history-indicated cerclage alone. Four of the studies were retrospective cohort studies [8] [9] [10] 19 and one was a randomized trial. 45 Four of the studies were carried out in the USA [8] [9] [10] 19 and one was done in
Israel. 45 Two of the studies were published in 2018, 10, 19 in 2016, 8 in 2014 9 and one in 1985. 45 All the studies included women with singleton pregnancies and a history of prior spontaneous preterm birth. Exclusion criteria were quite uniform across all the studies at baseline. These included a history of multiple gestations and of therapeutic cerclage (history or ultrasound-indicated cerclage).
Other exclusion criteria related to specific studies include delivery at an outside institution, 8 [8] [9] [10] 19, 45 All five studies were powered for their primary outcomes and some of the common secondary outcomes.
Quality assessment of the included studies performed using the ROBINS-I tool for cohort studies is shown in Table 1 . Most of the included studies showed an overall good rate with regard to bias due to selection of participants and measurement of interventions, and in the selection of the reported results of the study groups.
The main weaknesses of these studies were their retrospective designs, small sample size and the lack of information on the duration of follow up. For the most part, the participants in these studies were clinically heterogeneous, with women having one, two, three or more prior preterm births. Also, all the studies ideally excluded women with risk factors that predispose to preterm birth at baseline and contraindications to cerclage placement such as multiple gestations, more than one cerclage in index pregnancy, lethal congenital fetal anomalies and stillbirth. The studies also had methodological heterogeneity, including differences with respect to number of participants in the study arms and paucity of information about study follow up.
| Synthesis of the results
We investigated statistical heterogeneity mainly using the Q statistic, I 2 and the τ 2 . A priori, we specified a Q statistic of <.1 as statistically significant, and an I 2 statistic of 25%-50%, 51%-75% and 76%-100% as low, moderate and high heterogeneity, respectively.
We also visually examined the confidence intervals of the summary estimates in the Forest plots for overlap. With respect to our primary and secondary outcomes, an I 2 statistic of <25%, a Q statistic of P < .01, and a τ 2 of <1 in the primary outcome suggest low het- .45-1.65) (Figure 2) . Preterm birth at <28 weeks was evaluated in 4 studies. [8] [9] [10] 19 Meta-analysis of these studies demonstrated a 15% reduction in the risk of preterm birth at <28 weeks in women treated with prophylactic cerclage compared with history-indicated cerclage+17-OHPC. However, this risk reduction was not shown to be statistically significant at the 95% level (RR .85, 95%
CI .54-1.32) (Figure 3 ). Two studies evaluated preterm birth at <32 weeks as a secondary outcome. 9, 10 The meta-analysis of these studies demonstrated a 26% reduction in the risk of preterm birth in women treated with history-indicated cerclage alone compared with history-indicated cerclage+17-OHPC. This risk reduction was not shown to be statistically significant at the 95% level (RR .74, 95% CI .40-1.38) (Figure 4) .
Preterm birth at <37 weeks was evaluated in five studies. Length of neonatal intensive care unit (NICU) stay, mean gestational age at delivery, fetal/neonatal death, neurological morbidity, neonatal sepsis and a composite of severe neonatal morbidity were assessed in the included studies (Figures 9-14 ). There were no statistically significant differences in outcomes comparing cerclage alone with cerclage+17-OHCP groups. Subgroup analysis was done to evaluate the outcome of preterm birth with respect to the number of prior spontaneous preterm births in the studies-1 or 2 histories of prior spontaneous preterm births (4 studies) 8 10 . The results were similar to the main analysis ( Figure 15 ).
Publication bias was assessed using funnel plots (Figures 16-18 ).
The funnel plots are scatterplots of the estimated effect size (relative risk estimates) of maternal and fetal outcome measures plotted on the horizontal axis against the reciprocal of standard error of the estimated effect on the vertical axis for the studies identified. Formal publication bias assessment was also done using Egger's test. Egger's test results
were P = .02 for preterm birth at <24 weeks, .04 for preterm birth at <28 weeks, P = .01 for preterm birth at <32 weeks, and P = .03 for preterm birth at <37 weeks of gestation, suggesting asymmetry.
| D ISCUSS I ON
This systematic review and meta-analysis demonstrated no differences in spontaneous preterm birth reduction in women with prophylactic cerclage alone compared with women who received cerclage and adjuvant intramuscular 17-OHPC supplementation. Even with subgroup analysis, the non-significant effect of prophylactic cerclage+17-OHPC on preterm birth remained.
Though there was a trend toward a reduced risk of spontaneous preterm birth at <24, <28, <32 and <37 weeks of gestation in women who received history-indicated cerclage alone compared with those who received both therapies, the summary estimates of effect did not reach statistical significance. There was a trend towards a reduced risk of respiratory distress syndrome and necrotizing enterocolitis, but the summary with history-indicated cerclage+17-OHPC. it can sometimes be difficult to ascertain whether ruptured membranes occurred before or after the onset of uterine contractions in women with a history of mid-trimester pregnancy loss. In part, the lack of clarity that surrounds prophylactic cerclage in this setting is fostered by uncertainty in identifying those women who will genuinely benefit from its use (ie those with genuine cervical insufficiency or truly increased risk of early preterm delivery), 50, 51 hence the rationale for some practitioners in clinical practice to Our study has several strengths. The most important strength of our work rests on the fact that our systematic review and meta-analysis focused only on studies comparing 17-OHPC plus his- would suggest a possible publication bias. However, assessment of publication bias in this review is particularly difficult given that the number of studies were small (5 studies); funnel plots are thought to be unreliable methods of investigating potential bias if the number of studies is <10. Different provider experience in cerclage placement and number of cervical cerclage stitches placed (1 vs 2 or more reinforcement cerclages) may also have affected our results. The overall quality of evidence, as assessed by GRADE, was low or moderate for most of the observed outcomes. For example, the GRADE evidence was low for preterm birth at <28 and 32 weeks of gestation, respiratory distress syndrome and necrotizing enterocolitis; there was moderate GRADE evidence for preterm birth at <37 weeks of gestation and fetal birthweight.
Finally, this study was planned as a meta-analysis of all available studies comparing prophylactic cerclage+17-OHPC with cerclage alone, and the lack of statistically significant differences in outcomes may be related to being underpowered outcomes. The ideal method to compare the effectiveness and safety of 17-OHPC and prophylactic cerclage and prophylactic cerclage alone in women with a history of prior spontaneous preterm is by performing a direct comparison with a randomized controlled clinical trial. However, it is uncertain whether there will be such a randomized trial in the near future. We conducted a sample size calculation to determine the number of participants required to conduct such a trial. Assuming a 15% reduction in the frequency of preterm birth at <24 weeks of gestation from the prophylactic cerclage-alone group to the 17-OHPC plus prophylactic cerclage group, 1400 patients (700 F I G U R E 1 8 Funnel plot, preterm birth at <37 wk of gestation.
[Color figure can be viewed at wileyonlinelibrary.com] randomized to each group) would be required for this study to have 80% power and a type 1 error rate of 5%. In the absence of such a trial, the findings of this systematic review and metaanalysis provide some evidence to counsel patients and inform physician providers of the efficacy of adjuvant 17-OHPC in women with prophylactic cerclage. 
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